A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Eribulin (Primary) ; Capecitabine
- Indications Early breast cancer; Male breast cancer
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 18 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Nov 2013 Planned End Date changed from 1 Nov 2012 to 1 May 2014 as reported by ClinicalTrials.gov.
- 16 May 2013 Results will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2013).